Introduction
C-type lectin receptors (CLRs) recognize defined carbohydrate moieties, the "C" indicating Plasmacytoid DCs (pDCs), also known as natural interferon-producing cells, are APCs playing an important role in the immune balance 7, 8 . Resting pDCs induce mostly regulatory responses, while activated pDCs secrete large amounts of IFN-α and -β as well as chemokines 7, 9 . To identify microbial intruders they predominantly express TLR7 and TLR9 allowing them to respond to single stranded RNA and DNA viruses 10 . PDCs induce Th1 polarization 11 and are crucial for initiating and sustaining anti-viral immune responses by activating NK cell-mediated lysis of infected cells and by protecting uninfected cells from NK cytolytic activity. PDCs efficiently present viral antigens after infection and induce virusspecific primary and secondary CD4 + and CD8 + T cell responses 12 . Still little is known about antigen uptake by pDCs. Recently, a cooperative interaction between TLR9 and FcγRII on human pDCs was demonstrated in response to DNA-containing immune complexes isolated from patients with systemic lupus erythematosus. FcγR-mediated uptake of these immune complexes into endosomes containing TLR9, led to pDC activation 13 . Furthermore, we have 3 only.
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Increasing evidence suggests that pDCs not only express TLRs for pathogenrecognition and FcγRII for uptake of opsonized antigens, but also CLRs. So far, functional expression of the CLR BDCA-2 by human pDCs has been demonstrated. Antibody triggering induced BDCA-2 internalization and inhibited TLR9-mediated IFN-α production 15 .
Interestingly, BDCA-2 does not contain an intracellular signaling motif. Among the known human CLRs DCIR and DCAL-2 are the only ones containing intracellular immune receptor tyrosine-based inhibition motives (ITIMs). DCAL-2 expression is restricted to myeloid DCs 16 , while DCIR expression has been demonstrated on various APCs such as B cells, monocytes and myeloid DCs 17 .
DCIR ligands have not yet been identified. Initial functional studies in B cells with chimeric molecules containing the DCIR cytoplasmic domain indicated
that co-ligation of the B cell receptor with the chimeric DCIR molecules led to a decrease in overall protein tyrosine phosphorylation and reduced Ca 2+ flux 18 .
In the present study we demonstrate that DCIR is expressed by human pDCs.
Moreover, DCIR targeting inhibits TLR9-induced IFN-α production and results in antigen uptake and presentation by human pDCs.
Materials and Methods

Cells and reagents
All reagents were purchased from Sigma unless indicated otherwise. PDCs were isolated from
PBMCs by positive selection with anti-BDCA-4 antibody-coated magnetic beads (Miltenyi) and cultured in X-Vivo15 medium (Cambrex)/ 2 % human serum and 10 ng/ml IL-3. Secondary antibodies for FACS analysis were PE-(BD) or Alexa647-labeled (Molecular Probes). For confocal imaging, donkey anti-goat Alexa647-and isotype-specific goat antimouse Alexa488-and Alexa647-labeled secondary antibodies were used (Molecular Probes).
cDNA constructs
cDNA was generated from mRNA of human immature monocyte-derived DCs. The following DCIR primers were used in PCR reactions (Forward primer: 5'-ATG ACT TCG GAA ATC ACT TAT G-3', reverse primer: 5'-CTT GGG GAA TCC GGT ATT AC-3'). The DCIR coding sequence was cloned into a pEGFP-N1 vector in which EGFP had been replaced by a 5 only.
For personal use at PENN STATE UNIVERSITY on February 22, 2013. bloodjournal.hematologylibrary.org From hemagglutinin (HA)-tag or into pEGFP-C1 (BD Biosciences Clontech). Constructs were checked for correct reading frame and mutations at the department of Anthropogenetics (NCMLS, Nijmegen, The Netherlands). The human BDCA-2 construct was a kind gift of J.
Schmitz (Miltenyi Biotec, Bergisch-Gladbach, Germany). The human HA-tagged clathrin wildtype and dominant-negative constructs were generously provided by Onno Kranenburg (Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands).
Western blot
Cells were lysed in lysis buffer containing 150 mM NaCl, 10 mM TrisHCl pH 7.5, 2 mM MgCl 2 , 1 % triton-x100, 2 µg/ml aprotinin, 2 µg/ml leupeptin and 1 mM PMSF. 5 % β-mercaptoethanol was added. Samples were separated by polyacrylamide gel electrophoresis and blotted onto nitrocellulose membranes. Membranes were stained with goat anti-DCIR antibodies. Antibody signals were detected with horse radish peroxidase-coupled secondary antibodies using an enhanced luminescence detection kit (Pierce).
DCIR detection by confocal laser scanning microscopy
CHO-DCIR-EGFP cells were allowed to adhere to fibronectin-coated cover slips, fixed in 1% paraformaldehyde in PBS and permeabilized with 0.1 % triton-x100. Cells were incubated with murine monoclonal anti-DCIR antibodies for 30 min at 4 °C. Unbound antibodies were washed away. Cells were stained with goat anti-mouse IgG1-Alexa488. Isotype control antibodies did not show any staining. Cells were mounted in mowiol and analyzed by CLSM (Biorad MRC1024).
DCIR cross-linking assays
Flat bottom 96-well plates were coated with murine anti-DCIR or matched isotype control antibodies (mIgG1) at a concentration of 10 µg/ml in PBS for 2 h at 37 °C. Unbound antibody 6 only.
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DCIR internalization assays
Cells were incubated with goat polyclonal anti-DCIR, murine monoclonal anti-BDCA-2 or anti-MHC class I antibodies (10 μg/ml) in medium for 30 min on ice. Unbound antibodies were washed away and cells were incubated at 37 or 4°C for various time points. The amount of Ab complexes remaining on the cell surface was then determined by FACS analysis after staining cells with anti-mouse IgG-PE or anti-goat-IgG-Alexa647 secondary antibodies.
To detect internalized DCIR or BDCA-2 protein cells were first incubated for 30 min on ice with polyclonal goat anti-DCIR or monoclonal anti-BDCA-2 antibodies followed by incubation with donkey anti-goat-IgG-Alexa647 or goat anti-mouse-IgG1-Alexa647 for 30 min on ice. After incubation at 37 and 4 °C for various time points, cells were fixed, mounted on poly-L-lysine-coated cover slips and counterstained with mouse anti-MHC class I (10 µg/ml) antibodies followed by goat-anti-mouse IgG2a-Alexa488 for CLSM. For detection of internalized receptors by FACS surface antibodies were stripped off by shifting pH to 2.5. To inhibit clathrin-mediated endocytosis cells were incubated in hypertonic media. Incubation in media containing 450 mM sucrose results in disruption of clathrin-coated pits and induces formation of non-functional so-called "clathrin microcages". This process is fully reversible once cells are returned into isotonic media 19, 20 .
Antigen targeting
PBLs and pDCs were isolated from melanoma patients participating in ongoing DC For personal use at PENN STATE UNIVERSITY on February 22, 2013. bloodjournal.hematologylibrary.org From informed consent was obtained from all patients. Antigen-pulsed monocyte-derived DCs (gp100 peptides, tyrosinase peptide and KLH) were administered intravenously and intradermally. PDCs were isolated from apheresis products and incubated at 4 °C with anti-DCIR-mAb-and anti-DC-SIGN-mAb-KLH (both murine IgG1) conjugates generated as described previously 5 . Binding of both conjugates to DCIR was examined with a CHO cell line stably expressing DCIR and untransfected CHO cells. Cells were labelled for 30 min on ice with the conjugates, washed and counterstained with rabbit polyclonal anti-KLH and goat
anti-rabbit-IgG-Alexa647 antibodies. To block anti-DCIR-mAb-KLH binding pre-incubations with anti-DCIR or isotype control antibodies were performed. As control, pDCs were incubated with KLH or with KLH and patient-derived post-vaccination serum containing anti-KLH antibodies. PDCs were washed and co-cultured with KLH-responsive PBLs at 37°C.
Pre-treatment with anti-DCIR antibody was performed for 30 min at 4°C followed by incubation with anti-DCIR-mAb-KLH conjugates. All pDCs were cultured in IL-3. CpG-C (5 µg/ml) was added to pDC samples. After 4 d of co-culture, a titrated thymidine incorporation assay was performed. Titrated thymidine (1 µCi/well; MP Biomedicals) was added to the cell cultures and incorporation was measured after 16 h.
Cytokine production
pDCs (5x10 4 ) were stimulated with CpG-C M-352 (5 µg/ml). Supernatants were collected after 6 to 24 h, and IFN-α production was analyzed with murine monoclonal capture and HRP-conjugated anti-IFN-α antibodies (Bender) using standard ELISA procedures. IL-6, IL-10, IL-12 and TNF-α production were measured using the Luminex technology, a beadsbased cytokine detection system, according to the manufacturer's instructions (Biorad/Luminex).
Statistical analyses 8
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Significance was accepted at the p≤ 0.05 level.
Results
Human pDCs express the CLR DCIR
To study CLR expression, pDCs were isolated by positive selection using anti-BDCA-4- 
TLR9-induced pDC maturation reduces DCIR expression
To study the effects of pDC maturation on CLR expression, freshly isolated pDCs were cultured in medium containing IL-3 plus the TLR9 ligand CpG-C. PDC activation using these conditions led to a significant reduction of DCIR and BDCA-2 surface levels to 31 +/-14 % for DCIR (p≤0.001) and to 14 +/-10 % (p≤0.001) for BDCA-2 and ( For personal use at PENN STATE UNIVERSITY on February 22, 2013. bloodjournal.hematologylibrary.org From (data not shown). Next to TLR9 human pDCs are known to express only TLR7 8, 23 . We therefore also included the TLR7/8 ligand R848 and the TLR7 ligand loxoribine to analyze the effects of TLR7 triggering on DCIR expression in pDCs. TLR7 stimulation by both compounds reduced DCIR expression on pDCs to a similar extent as TLR9 triggering with CpG-C (data not shown). We note that incubation in medium containing IL-3 already leads to a decrease in DCIR and BDCA-2 surface levels (data not shown), in line with the finding that IL-3 induces transition from pre-pDCs to pDCs 24 . Addition of the TLR9 ligand CpG-C, however, further reduces DCIR and BDCA-2 expression.
DCIR triggering does not affect TLR9-induced co-stimulatory molecule expression by human pDCs
DCIR contains an intracellular ITIM motif suggested to play a role in immune inhibition. We therefore hypothesized that receptor triggering may inhibit immune activating processes. In response to activating stimuli, such as TLR9 ligands, pDCs express the co-stimulatory molecules CD40 25 , CD80, and CD86 which play a central role in T cell activation 26 . Freshly isolated pDCs were cultured on plates coated with murine anti-DCIR or matching isotype control antibodies. Addition of CpG-C induced robust CD40, CD80, and CD86 upregulation after 24 h when compared to medium controls. However, DCIR triggering did not influence expression of the co-stimulatory molecules ( Figure 2B ). The same was true for MHC class II (data not shown). Inhibition of TLR9-mediated CD40, CD80 or CD86 upregulation is therefore not a mechanism of potential DCIR-mediated immune suppression.
DCIR triggering inhibits TLR9-mediated IFN-α production by human pDCs
Peptides comprising the phosphorylated cytoplasmic ITIM domain of DCIR have been shown to interact with the tyrosine phosphatase SHP-1 27 , which inhibits cytokine signaling 28 . PDCs produce large amounts of IFN-α during the first 12 hours of activation with TLR ligands 24 .
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We therefore analyzed whether DCIR cross-linking would influence TLR9-mediated IFN-α production. PDCs were cultured on plates coated with anti-DCIR or matching isotype control antibodies and stimulated with CpG-C. DCIR-triggering clearly inhibited TLR9-induced IFN-α production by 40 % (Figure 2C , right) relative to isotype control. Inhibition could be detected after 6-8 h in the time course experiment depicted in Figure 2C (left). Furthermore, DCIR-triggering also reduced TLR9-mediated TNF-α production by 28 %, while IL-6 remained unaffected ( Figure 2D ). In line with recent reports in literature, we did not detect any IL-10 or IL-12 production by human pDCs after TLR9-triggering 29, 30 . As described by Dzionek et al. 15 , triggering with anti-BDCA-2 antibodies performed in parallel experiments resulted in 80 to 90 % reduced IFN-α production in response to CpG-C (data not shown).
Since we had observed reduced DCIR expression on pDCs after TLR7 triggering, we also analyzed the effects of DCIR cross-linking on TLR7-mediated IFN-α production. We found that TLR7 triggering induced IFN-α production by pDCs, albeit much less and less consistent than TLR9 triggering (up to 70 times more IFN-α with CpG-C than with R848). We did, however, not observe significant inhibition of TLR7-mediated IFN-α production by DCIR cross-linking (data not shown). In summary, DCIR-triggering inhibited TLR9-mediated IFN-α secretion by 40 +/-3 % (p≤0.0002, n=3) ( Figure 2C , right).
Cell surface DCIR is internalized into pDCs after receptor triggering
A putative mechanism for DCIR to inhibit TLR9-mediated IFN-α production could be modulation of TLR9 signaling events. This would most likely require DCIR endocytosis and trafficking into endosomal compartments containing TLR9. To study this hypothesis DCIR internalization experiments were performed. PDCs were incubated with anti-DCIR antibodies.
Incubation at 37 °C clearly reduced the cell surface level of DCIR by 50 % when compared to control cells incubated at 4 °C ( Figure 3A, left) . Under the same conditions surface BDCA-2 11 only.
For To visualize DCIR localization after antibody triggering, pDCs were analyzed by confocal laser scanning microscopy (CLSM). At 4 °C DCIR clearly co-localizes with MHC class I at the cell surface ( Figure 3A, right) . Once the incubation temperature is elevated to 37 °C, DCIR is internalized and can be detected in intracellular vesicular structures. In line with literature 15 , BDCA-2 was also internalized ( Figure 3A , right).
DCIR internalization is clathrin-dependent
Next, the mechanism underlying DCIR internalization was investigated in more detail.
Receptor-mediated endocytosis is often clathrin-mediated
31
. Clathrin-dependent endocytosis can be inhibited by incubation in hypertonic media. PDC incubation with anti-DCIR and fluorochrome-conjugated secondary antibodies at 37 °C induced DCIR internalization.
Disruption of clathrin-coated pits in hyper-osmolar medium resulted in total inhibition of DCIR internalization in pDCs which was fully restored after sucrose washout ( Figure 3B ).
The low frequency of pDCs in peripheral blood hampers their biochemical analysis.
Therefore, to further substantiate clathrin-dependence of DCIR endocytosis, a CHO cell line stably expressing human DCIR-EGFP was generated ( Figure 4A ). Vesicle fissure in clathrinmediated endocytosis is known to be dynamin-dependent. CHO-DCIR-EGFP cells were cotransfected with dynamin-wildtype (WT) or -dominant negative (DN) constructs. Cotransfection of DN-dynamin resulted in 50 % inhibition of DCIR internalization ( Figure 4B and Supplementary figure 2). Together these data reveal clathrin-dependence of DCIR internalization.
DCIR-mediated uptake leads to antigen presentation
As pDCs rapidly internalized DCIR upon mAb binding we evaluated the induction of T cell responses to KLH by targeting DCIR on human pDCs. Hereto, we generated anti-DCIR-
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mAb-KLH (anti-DCIR-KLH) and anti-DC-SIGN-mAb-KLH (anti-DC-SIGN-KLH)
conjugates. While anti-DCIR-KLH bound DCIR-expressing CHO cells, anti-DC-SIGN-KLH did not ( Figure 5A, left) . Anti-DC-SIGN-KLH was functional, as it did bind to monocytederived DCs (data not shown). The specificity of these findings was confirmed by blocking with anti-DCIR antibodies, but not by pre-incubation with isotype control (Figure 5A, right) .
Next, pDCs and PBLs were isolated from apheresis products of melanoma patients participating in ongoing clinical DC vaccination trials that include KLH as a helper antigen.
Patient-derived isolated pDCs were loaded on ice with protein conjugates consisting of KLH and DCIR-mAb, KLH and DC-SIGN-mAb or KLH alone. As a positive control KLH was targeted to FcγRII via anti-KLH IgG antibodies 14 . PDCs were then incubated with IL-3 and matured with CpG-C. Fresh patient-derived PBLs were added to the pDCs and proliferation was measured after four days of co-culture without adding any exogenous cytokines.
Strikingly, KLH-targeting via DCIR induced a strong proliferative recall response and was as effective as targeting via FcγRII. Moreover, pDC pre-incubation with anti-DCIR antibodies blocked the observed targeting effect to background levels demonstrating the specificity of the response. Since pDCs do not take up soluble exogenous antigens in a receptorindependent fashion 32 , anti-DC-SIGN-mAb-KLH conjugates or KLH alone did not induce proliferation above background levels ( Figure 5B ). DCIR is thus not only internalized after cross-linking, but it also delivers its antigenic cargo into the antigen presentation pathway of pDC resulting in T cell proliferation.
Discussion
PDCs are the major type I IFN producers and play a crucial role in the anti-viral immune defense 8, 33 . To detect invading pathogens they express receptors such as TLR7 and 9 and FcγR II. Still little is known about the role of CLRs in human pDC biology. In this study, we demonstrate not only that human pDCs express the CLR DCIR, but also that DCIR triggering For personal use at PENN STATE UNIVERSITY on February 22, 2013. bloodjournal.hematologylibrary.org From response to TLR9 stimulation is at least in part mediated via IFN-α, since it induced DCIR down-regulation by 78% compared to a down-regulation by 74% induced by CpG-C.
Addition of TNF-α on the other hand, did not lead to significant reduction of DCIR expression (data not shown).
PDCs are known to express only TLR7 next to TLR9 8, 23 . In initial experiments we therefore also included the TLR7/8 ligand R848 and the TLR7 ligand loxoribine. TLR7
stimulation by both compounds reduced DCIR expression on pDCs to a similar extent as TLR9 triggering with CpG-C (data not shown). In line with these data, we found that TLR7
triggering also induced IFN-α production by pDCs, albeit much less than TLR9 triggering.
We did, however, not observe significant inhibition of IFN-α production following TLR7
activation.
Cross-talk between TLRs and CLRs on myeloid DCs has been demonstrated for the immune receptor tyrosine-based activation motif (ITAM)-containing dectin-1 and TLR2 and
results in greatly increased TNF-α production 36, 37 . Dectin-1 is an APC β-glucan receptor that is functionally regulated by tetraspanin CD37 38 . Furthermore, the CLR DC-SIGN has been shown to inhibit TLR activation of myeloid DCs by Mycobacterium tuberculosis after binding to its cell wall component ManLAM 39 . Cross-talk between CLRs and TLRs thus represents a more general mechanism to fine-tune the function of myeloid DCs and now also pDCs.
DCIR function in pDCs goes further than inhibiting TLR9 signaling. The data presented show that DCIR functions as an endocytic receptor on human pDCs and that it is connected to the clathrin-mediated receptor uptake machinery, which further supports the notion that DCIR delivers its cargo to the endosomal/lysosomal compartments 40 For personal use at PENN STATE UNIVERSITY on February 22, 2013. bloodjournal.hematologylibrary.org From DCIR-mediated uptake to evaluate cross-presentation. Ovalbumin was readily internalized after DCIR-mediated uptake. We did, however, not observe any CD8+ T cell response to these pDCs (data not shown) while proliferation of CD4+ T cells was readily observed . In addition, extensive mouse pDC studies have so far not been able to show cross-presentation by murine pDCs 43 . Moreover, antigen uptake via murine DCIR2 into myeloid DCs has recently been shown to induce only helper T cell responses and no MHC class I antigen presentation 4 . These findings and our own data also imply that human DCIR is not likely to be involved in direct cross-presentation. Instead, the IFN-α pDCs produced in response to TLR ligands has been shown to promote cross-presentation of exogenous antigens by myeloid DCs 44-46 .
In summary, the data demonstrate that DCIR is a new human pDC endocytic receptor that controls TLR9-mediated IFN-α production. DCIR on pDCs mediates antigen uptake. For personal use at PENN STATE UNIVERSITY on February 22, 2013. bloodjournal.hematologylibrary.org From inhibits TLR9-mediated IFN-α production by human pDCs. PDCs were incubated on plates coated with murine anti-DCIR or isotype control antibodies. Cells were stimulated with CpG-C (5 µg/ml) or left unstimulated (control), and IFN-α production was analyzed after 6 and 8 h (left, one representative donor). DCIR triggering inhibited IFN-α production by 40 +/-3 % compared to isotype control samples (p≤0.00002) (right, data represent the mean ± SEM of three independent experiments; incubation time 8-24 h). D) DCIR triggering inhibits TNF-α but not IL-6 production. Cells were treated as in Figure 2C ) and TNF-α and IL-6 secretion were analyzed. DCIR triggering inhibited TNF-α production by 28 +/-5 % (p≤0.0025), while it did not affect IL-6 production (data represent the mean ± SEM of three independent experiments; incubation time 6-24 h). There was no production of IL-10 or IL-12 detectable (data not shown). Figure 5B For personal use at PENN STATE UNIVERSITY on February 22, 2013. bloodjournal.hematologylibrary.org From
